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Biomarker research of psychiatric disorders is delayed by symptom pattern-
related diagnostic categories that are only distantly associated with biological
mechanisms. In neuropsychiatric disorders that have high heritability
(schizophrenia, autism, Alzheimer’s disease), genomic research led to signifi-
cant genome-wide association study (GWAS) results by increasing the number
of subjects in case--control studies, and thus provided new hypotheses regard-
ing the aetiology of these disorders and possible targets for research of new
treatment approaches. In contrast, in moderately heritable psychiatric disor-
ders (anxiety disorders, unipolar major depression), the development of symp-
toms, in addition to risk genes, is more dependent on the presence of specific
environmental risk factors. Thus, controlling for heterogeneity, and not sim-
ply increasing the number of subjects, is crucial for further significant psychi-
atric GWAS findings that warrant the collection of more detailed individual
phenotypic data and information about relevant previous environmental
exposures. Gene--gene interactions (epistasis) and intermediate phenotypes
or psychiatric and somatic co-morbidities, by identifying similar cases within
a diagnostic category, could further increase the generally weak effects of
individual genes that limit their usefulness as biomarkers. In conclusion, we
argue that methods that are suitable to identify biologically more homoge-
neous subgroups within a given psychiatric disorder are necessary to advance
biomarker research.
Keywords: biomarkers, gene--environment interaction, gene--gene interaction, heritability,
intermediate phenotype, psychiatric disorders
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1. Introduction
Psychiatric disorders impose enormous medical and economic burdens on patients,
their families and healthcare providers worldwide. Therefore, there is an unmet
need to improve early diagnosis and thus treatment strategies including prevention.
However, currently used diagnosis and disease entities in psychiatry are largely based
on clinical phenomenology and lack biological validity, which is a major limitation
in identifying biomarkers for psychiatric disorders.
In the past decade, genetic research was expected to aid in the definition of psy-
chiatric disease entities themselves by identifying new biological pathways. In some
neuropsychiatric disorders that have high heritability, such as schizophrenia, autism
and Alzheimer’s disease (Table 1), increasing the number of persons in case--control
studies led to significant genome-wide association study (GWAS) results, and thus
provided new hypothesis regarding the aetiology of these disorders and directed
research to new treatment approaches [1]. However, we are still missing considerable
amount of heritability even in these disorders that might be partially explained by
gene--environment interactions or complex interplay between genes [2]. In addition,
in psychiatric disorders with moderate heritability, such as most anxiety disorders
and unipolar major depressive disorder (MDD; Table 1), environmental factors
have an even more important role to determine or moderate genetic effects in the
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development of symptoms that serve as a basis for the diagno-
sis. Gene--environment interactions may have different effects:
i) in case of biological interaction, the genetic effect depends
on the presence or absence of an environmental factor;
ii) quantitative interaction results in the same direction of
effect in both genotype groups but the effect sizes differ
according to the environmental exposure; and iii) qualitative
interaction may produce opposite direction of effects in dif-
ferent genotype carriers [2]. The case--control studies that do
not contain detailed individual data about relevant previous
environmental factors and exposures could have not led to sig-
nificant GWAS results so far when simply increasing the
numbers in these moderately heritable disorders [1]. In a very
recent study, four risk loci with shared effects on five major
psychiatric disorders (autism spectrum disorder, attention
deficit-hyperactive disorder, bipolar disorder, MDD and
schizophrenia) were identified after including about 33,000
cases and 28,000 controls in the analysis [3]. Among those,
rs2535629 on chromosome 3 showed the smallest p value
and thus the strongest association signal, but even with this
polymorphism, no association was noted in a large replication
dataset of MDD, suggesting that the potential function of this
genetic region in MDD is ambiguous [3]. In a study about the
possible role of serotonin transporter gene (SLC6A4) pro-
moter polymorphisms (5-HTTLPR) in the development of
MDD and low mood, 5-HTTLPR had no significant effect
in the whole population. In contrast, it doubled the signifi-
cant effects of threatening life events (TLEs) when both
parameters (5-HTTLPR and TLE) were included in the
model [4]. A recent large meta-analysis, including > 40,000
subjects, provided robust evidence that 5-HTTLPR moder-
ates the relationship between life stresses and depression [5].
Thus, despite the methodological and statistical difficulties,
in the future the inclusion of environmental factors in datasets
and analysis is crucial for psychiatric disorders with moderate
heritability (e.g., MDD, anxiety disorders, drug/alcohol/
tobacco dependence), and even in those with high heritability,
the inclusion of environmental factors will shed light on fur-
ther genetic components not discovered yet.
However, there is a general limitation of GWAS studies,
namely the small effect size of genes on phenotypic variance.
Even in the few variants that markedly change protein
structure or function, the association with complex psychiatric
phenomena, such as diagnostic categories, is weak, making it
difficult to use them in personalised diagnosis. One possible
approach to increase our understanding of genetic effects is
to investigate gene--gene interactions or epistasis, where the
combination of two or more polymorphisms results in
marked biological differences among the groups. Double
knock-out animal studies demonstrated the existence of addi-
tive genetic effects, where the measured phenotype became
more severe with increasing number of risk alleles, but also
supported the importance of non-additive genetic interactions
in which case new phenotypes occurred [6]. Similar evidence
has been described in humans between genes of brain-
derived neurotrophic factor (BDNF) and 5-HTTLPR on a
key brain circuitry relevant in depression [7] and between pro-
moter polymorphisms of cannabinoid receptor type 1 (CB1)
gene (CNR1) and SLC6A4 on anxiety trait and tempera-
ment [8]. These types of interactions may serve to identify
groups of patients with highly increased or reduced risk for
certain drug effects or environmental factors [9]. In addition,
gene--gene interaction studies pointed out that these effects
are apparent when continuous traits are investigated and
rarely, if ever, apparent at a diagnosis level [6,9].
Biomarkers are by definition measurable indicators of
normal or pathological biological processes and may be influ-
enced by environmental factors, such as drug treatment [10].
By measuring specific biomarkers (Figure 1), we can gather
information about the so-called intermediate phenotypes
that in neuropsychiatry represents neurobiological processes
with a causal role in the disease pathway [11]. Although
intermediate phenotypes are interpreted in several ways,
we adopted the definition of Meyer--Lindenberg and
Weinberger [12] and presumed that intermediate phenotypes
are genetically determined traits (Figure 1). Thus, different
intermediate phenotypes, and those specific biomarkers that
characterise them, can be crucial to identify otherwise weak
or unobservable genetic effects on complex phenotypes of
interest (e.g., diagnosis or therapeutic outcome) by reducing
the heterogeneity. It is important to note that the terms inter-
mediate phenotype and endophenotype are not interchange-
able because endophenotypes do not necessarily mediate
genetic effects to disorders [13]. As an example of the usefulness
Table 1. Heritability of psychiatric disorders and summary of relevant genetic studies.
Phenotype Heritability* Candidate gene studies GWAS G  E
Unipolar depression 0.37 +? -- +
Bipolar affective disorder 0.85 +? + --
Schizophrenia 0.81 +? + --
Anxiety disorders 0.32 +? -- +
Autism 0.90 + + --
Alzheimer’s disease 0.70 + + --
*Heritability data are based on Uher, Molecular Psychiatry, 2009 [22]; the summary is based on the literature listed in References section.
+?: Promising results but with some controversy; +: Supported by replications or big meta-analysis studies; --: No or mainly controversial findings; GWAS: Genome-
wide association studies; G  E: Gene--environment interaction.
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of different intermediate phenotypes, we investigated the effect
of the CREB1--BDNF--NTRK2 pathway on depression. Using
rumination, a well-known cognitive intermediate phenotype
for depression, the major alleles of the CREB1 and BDNF
genes promoted the development of depression. However, in
case of history of childhood abuse, the minor alleles of the
same genes were risk factors for depression most likely by
altering the function of the hypothalamic--pituitary--adrenal
(HPA) axis, which is an alternative intermediate phenotype
in stress-related disorders [14]. Similarly, the 5-HTTLPR short
allele increases the risk of depression and anxiety in the pres-
ence of negative life events by increasing amygdala activity fol-
lowing stressful events, and predicts poorer antidepressant
response (Figure 2). But 5-HTTLPR short allele is also associ-
ated with better performance in several cognitive tasks and
increased social conformity (with similar results in non-
human primates) and with a more advantageous effect of
psychotherapy presumably because it alters the development
of limbic--cortical neuronal connections [15].
For psychiatric disorders, the aimed intermediate
phenotypes are mostly present in the brain, although some
exemptions exist (e.g., certain adverse reactions of drugs). Epi-
genetic changes, which alter gene expressions depending on
the environmental exposures, are therefore tissue and cell spe-
cific on the periphery; they may be fairly different from those
that happen in the central nervous system that is in the focus
of interest. Even in the brain, adjacent neurons and nuclei
may react differently to a given action or environmental stim-
ulus [16]. Thus, results from the analysis of peripheral bio-
markers are difficult and need caution to interpret. Because
local invasive sampling of the brain is not possible, the best
alternatives are imaging techniques. Functional magnetic res-
onance brain imaging (fMRI) with carefully selected psycho-
logical tasks and positron emission tomography (PET) using
specific tracers demonstrated that the functional activity of neu-
ral circuits, related to psychiatric phenotypes, are under the
influence of genes and environment. For example, one of the
most replicated finding is the influence of serotonin transporter
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Figure 1. The complex interaction of genes, environmental factors and intermediate phenotypes in biomarker research to
predict different endophenotypes and outcome variables. A given gene set represents a genetic pathway that influences a
specific biological process. Arcs between gene sets represent possible interactions (gene  gene, epistasis). Arrows originated
from gene sets depict genetic effects on intermediate phenotypes. Intermediate phenotypes, which denote genetically
determined neurobiological processes with causal role in the disease pathway, could be identified as biomarkers themselves
but usually difficult to measure directly. However, they could be characterised by using different selected more easily
measurable biomarkers (boxes in the middle). We suggest that those specific biomarkers are important and useful for
personalised treatment in neuropsychiatric diseases that are informative for intermediate phenotypes influenced by
environmental factors and could be used in the clinical diagnosis, outcome, therapeutic and/or side effect of drugs. Arcs
between biomarkers represent possible combination of different biomarkers that provide relevant information to predict
diagnosis, outcome or drug response/side effects. The environmental factors may cause epigenetic changes (e.g., up- or down-
regulation in the expression of particular genes) or direct alterations in the measurable biomarker (e.g., exposure to a
neurotoxin or brain trauma that disables or disconnects functional brain areas).
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gene (and life stresses) on negative emotion processing that can
be quantified by measuring amygdala activity and connectivity
between amygdala and prefrontal cortex (Figure 2) [12]. Further
studies demonstrated that these biomarkers are related to
depression and remission from the depressed state [17]. How-
ever, it has to be emphasised that these brain mechanisms are
not unique for specific psychiatric disorders which is in line
with the evidence that current diagnostic boundaries are artifi-
cial and high co-morbidities exist between different diagnostic
categories.
An emerging new field of biomarker research is to identify
not only psychiatric but somatic also co-morbidities that can
have shared pathomechanism. The aim of the so-called net-
work medicine is to utilise molecular relationships between
disorders that are strikingly different at a phenotypic level [18].
A good example is the high co-morbidity between depression
and type 2 diabetes that initiated research into the effects of
insulin in neurotransmission and neuroinflammation, and
its potential therapeutic use [19].
Finally, to identify biomarkers we have to carefully take
into account the phenotype we would like to predict as the
complex behavioural phenotypes, such as depression and
schizophrenia, or their modification by a drug, which are
dependent on several neurobiological processes (Figure 1) [20].
Markedly different or only partially overlapping genes and
biological processes are involved in the development of
symptoms that lead to the diagnosis; other pathways may
play a role in the disease outcome, again others in the thera-
peutic effects, and further processes in the side and/or adverse
effects of a given drug. In the development of tolerance, fur-
ther mechanisms may be involved. In addition, if we have a
drug that works by a different mechanism of action, binds
to different receptors and has a different chemical structure,
completely new biomarkers may be useful (Figure 1). For
example, biomarkers that could be influenced by both genetic
and environmental factors and are substrates of an actual
biological process, which is presumably involved in the path-
omechanism, may be seemingly perfect for the detection of
a drug or other treatment effect. However, in the case of
bapineuzumab treatment, a monoclonal antibody against
amyloid-b, the PET marker (11C-PiB) of cortical fibrillar
amyloid-b load in vivo provided evidence for the disappear-
ance of the protein after 78 weeks. Unfortunately, the mental
decline of the patients was not affected, suggesting that there
was a dissociation between the effects of the drug observed
by the promising marker and the symptoms targeted [21].
2. Expert opinion
Now it is widely accepted that psychiatric diagnoses and dis-
ease entities classified by clinical phenomenology do not
reflect pathogenic biological mechanisms. In case of highly
heritable psychiatric disorders, such as schizophrenia, autism
and Alzheimer’s disease, GWASs were able to identify com-
mon genetic risk variants by increasing the number of subjects
in case--control studies, and thus we gained new insight into
the possible aetiology of these disorders that triggered the
research of new treatment approaches. However, in psychiat-
ric disorders with moderate heritability (most anxiety disor-
ders and unipolar MDD), this method has not provided
significant GWAS results most likely because environmental
factors interact with genes to produce the symptoms that serve
as a basis for diagnosis. Variable environmental exposure
could introduce considerable heterogeneity, and thus case--
control studies that do not contain detailed individual data
about relevant previous environmental factors and exposures
did not, and very likely could not, lead to significant GWAS
results simply by increasing the numbers. In addition, analysis
of gene--environment interaction could have a major role to
improve our understanding of highly heritable neuropsychiat-
ric disorders as well. Another possible approach to increase the
generally weak effects of individual genes in psychiatry is to
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Figure 2. An example of usefulness of brain imaging intermediate phenotypes to identify risk gene and biomarker to
treatment response for depression. Life stresses (e.g., watching fearful or sad faces) activate the amygdalae in the brain. The
presence of a risk allele within the serotonin transporter gene (SLC6A4, 5-HTTLPR short allele) is associated with increased
amygdala activation and with altered connectivity between the amygdalae and prefrontal cortical (PFC) areas compared to
non-risk allele carriers during stressful situations. These biomarkers (amygdala activity and PFC--amygdala connectivity), which
could be reliably measured by fMRI using selected neuropsychological tasks, provide information how the brain processes
negative emotions. Impaired negative emotion processing is an intermediate phenotype that increases the risk of depression
and predicts poorer antidepressant response.
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investigate gene--gene interactions or epistasis. A different
strategy could be the introduction of the so-called intermedi-
ate phenotypes that are measurable, genetically determined
and environment-dependent neurochemical, anatomical,
physiological or psychological phenotypes with a causal role
in the disease pathway. Since these are mainly related to brain
function, functional brain imaging can provide useful inter-
mediate phenotypes for further genetic and biomarker studies.
It is also important to investigate psychiatric and somatic co-
morbidities with shared pathomechanisms to identify poten-
tial disease pathways. Because disease entities are not based
on biological processes in psychiatry, another key point is
that symptoms, disease outcomes, therapeutics or side effects
of drugs are dependent on several, mostly different or only
partially overlapping genes and biological processes.
In conclusion, the major challenge is to develop reliable meth-
ods and identify useful biomarkers to minimise heterogeneity
of patients within different psychiatric diagnostic categories
and get closer to the specific neurobiological processes typical
for the given, relatively homogeneous subgroup. Therefore, to
extend genetic studies to a more detailed intermediate pheno-
types and environmental exposures will be a key strategy for
future research to identify new treatment targets and the best
biomarkers for the different psychiatric phenotypes.
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